An official website of the United States government
On this page...
Need Help?
Have questions about this topic or need additional assistance?
Andrea Burnett-Hartman, PhD, MPH
Program Director, Clinical and Translational Epidemiology Branch
andrea.burnett-hartman@nih.gov
Danielle Carrick, PhD, MHS
Program Director, Genomic Epidemiology Branch
carrick@mail.nih.gov
Somdat Mahabir, PhD, MPH
Program Director, Environmental Epidemiology Branch
mahabir@mail.nih.gov
Mukesh Verma, PhD
Branch Chief, Methods and Technologies Branch
vermam@mail.nih.gov
Dana Wolff-Hughes, PhD
Program Director, Risk Factor Assessment Branch
dana.wolff@nih.gov
Overview
A biomarker is a biologic specimen that may be a marker of exposure to a substance, its metabolism, or an integration of exposure and metabolism. Biomarkers may also reflect host characteristics. Digital biomarkers are physiological and behavioral measures derived from digital technology that explain or predict health outcomes. Because biomarkers are sometimes related to risk of disease, they are important in cancer control research. To be useful in cancer epidemiology, applications of biomarkers should reduce misclassification of exposures and disease, enhance detection of exposure-disease associations, or increase opportunities for intervention.
NCI’s Epidemiology and Genomics Research Program (EGRP) is interested in the development of novel biomarkers as well as understanding how biomarkers can be used in risk factor assessment, early detection/screening of cancer, disease stratification, identifying environmental exposures that may lead to cancer, and as markers of nutrition that either promote or protect against cancer.
Funding Opportunities
NCI is currently participating in the following notices of funding opportunities that are relevant to biomarkers research:
- NOSI: Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers - expires July 2, 2025
- Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development - expires June 23, 2026
- PAR-25-170, UG3/UH3 - Clinical Trial Optional
- Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants - expires October 15, 2026
- PAR-24-304 (R01, Clinical Trial Not Allowed)
- Assay Validation of High Quality Markers for Clinical Studies in Cancer - expires October 15, 2026
- PAR-25-074 (UH2/UH3, Clinical Trial Not Allowed)
- PAR-25-075 (UH3, Clinical Trials Not Allowed)
EGRP joins with other NCI Divisions, Offices, and Centers and other Institutes and Centers at the National Institutes of Health (NIH) to fund grant applications submitted in response to notices of funding opportunities. View the full list of cancer control research funding opportunities.
EGRP also encourages investigator-initiated grant applications on topics related to biomarkers and cancer epidemiology.
Related NIH Research Resources
- Biospecimen Resources for Population Scientists
A list of links to biospecimen resources that may be of interest to cancer epidemiologists, including policies and best practices for biospecimen research and potential sources of biospecimens. - Early Detection Research Network (EDRN)
The Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI), brings together dozens of institutions to help accelerate the translation of biomarker information into clinical applications and to evaluate new ways of testing cancer in its earliest stages and for cancer risk. - National Institute of Environmental Health Science (NIEHS) Health Topics: Biomarkers
This compilation of resources includes studies, clinical trials, educational materials, NIEHS initiatives, and general information related to biomarkers.